SynthesisCancer immunology, immunotherapy : CII2026
First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort.
Tanya Ramadoss et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.